A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease
Figure 5
(a) Cells were stimulated with given concentrations of DHB for 6 h and mRNA levels of HO-1 analyzed via real-time PCR as described. (b) BV2 cells were stimulated with various concentrations of DHB for 24 h and whole cell lysates subjected to western blot analysis using antibody against HO-1 protein; * versus control. (c) Cells were pretreated with ZnPPIX (20 μM) for 30 min followed by co-treatment with DHB (100 μM) for another 1 h before LPS (100 ng/mL) addition. Conditioned media (CM) was collected after 24 h of LPS treatment and nitrite levels were determined using the Griess reagent. Each bar represents mean ± SEM from at least four independent experiments. * compared with the control group, ** compared with the LPS treated group, *** compared with the LPSDHB100 treated group. (d) BV2 NFκB-Luc cells were pretreated with HO-1 inhibitor ZnPPIX (20 μM) for 30 min followed by co-treatment with DHB (100 μM) for another 1 h before LPS (100 ng/mL) addition for 4 h. Cell lysates were assayed for luciferase activity (mean ± SE, ). * versus control, ** versus LPS.
